Kallmann syndrome

Kallmann syndrome (KS) is a rare genetic disorder characterized by the combination of hypogonadotropic hypogonadism (a deficiency of sex hormones due to impaired function of the hypothalamus and pituitary gland) and anosmia or hyposmia (absent or reduced sense of smell). It is a form of isolated gonadotropin-releasing hormone (GnRH) deficiency. The condition results from the failure of GnRH-producing neurons to migrate properly from the olfactory placode to the hypothalamus during embryonic development, which also disrupts the formation of the olfactory bulbs, explaining the impaired sense of smell. Kallmann syndrome primarily affects the reproductive and olfactory systems. In males, it typically presents with failure to enter puberty, micropenis, cryptorchidism (undescended testes), and infertility. In females, it manifests as primary amenorrhea (absence of menstruation) and lack of breast development. Additional features may include renal agenesis (absence of one kidney), cleft lip or palate, dental agenesis, synkinesia (mirror movements of the hands), hearing loss, and skeletal anomalies such as short metacarpals. The condition is significantly more common in males than females, with an approximate ratio of 4:1 to 5:1. Multiple genes have been implicated in Kallmann syndrome, including KAL1 (ANOS1, X-linked), FGFR1, FGF8, PROKR2, PROK2, CHD7, WDR11, and others, reflecting its genetic heterogeneity. Treatment focuses on hormone replacement therapy to induce and maintain secondary sexual characteristics and, when fertility is desired, pulsatile GnRH therapy or gonadotropin injections (FSH and hCG/LH) to stimulate gametogenesis. With appropriate treatment, most patients can achieve satisfactory pubertal development and fertility. Early diagnosis and intervention are important for optimizing bone health, psychological well-being, and reproductive outcomes.

Common questions about Kallmann syndrome